Management / QPPV

Edgar J. Fenzl, M.D., Ph.D.

Managing Director, QPPV

Edgar Fenzl is a physician with a doctorate in clinical pharmacology with more than 35 years of experience in pharmaceutical medicine. He has worked in a number of pharmaceutical companies and clinical research organizations, where he held ­appointments with increasing responsibilities as chief physician, head of clinical ­research units and managing director. Dr. Fenzl has overseen a large number of in-house, national and international clinical studies. He has supervised and managed phase I to IV clinical studies in pharmacokinetics, in a broad range of medical indications, as well as studies for OTC products. Dr. Fenzl is the author or coauthor of many publications on clinical development, Rx and OTC products. As head of clinical research for a number of companies he has supervised project leaders and medical advisors, and acted as Sponsors’ responsible medical officer for drug safety and regulatory issues. He has extensive experience in company organization and management, including ­company restructuring („reengineering“). As QP for Pharmacovigilance his current focus is on providing a personalized ­service for its clients and consulting on drug development and regulatory topics. He is Managing Director of FGK Clinical Research GmbH, FGK Clinical Research Kft. and FGK Representative Service GmbH and serves as a Director at FGK ­Clinical Research Limited.

Download CV (PDF: 115KB)

Anthony W. Fox, B.Sc., MBBS, M.Sc., LLM, M.D.(Lond), FRCP, DipPharmMed, DipFHI, CBiol

Managing Director

Tony Fox is a pharmaceutical physician with more than 30 years experience in large pharma, small pharma and biotech, both as a senior employee (then Glaxo Inc., North Carolina; Procter and Gamble, Norwich NY) and as an independent consultant.  He led clinical teams that obtained regulatory approval for Imitrex®, Amerge® and Ultiva®.  He was also formerly President of EBD Group (Carlsbad, California and Munich, Germany).  He holds  qualifying degrees in medicine and law, and a research doctorate in drug-receptor pharmacology, all from the University of London (UK).  He is a Fellow of the Royal College of Physicians, a Life Fellow of the Royal Society for the Encouragement of Arts, Manufactures and Commerce, and a Liveryman of the Worshipful Society of Apothecaries (with the Freedom of the City of London).  His numerous publications span pharmacovigilance, clinical and non-clinical toxicology, experimental medicine, clinical pharmacology and other industry-related subjects.

Download CV (PDF: 152KB)

Zurab Koberidze, M.D., Ph.D., MPH

Director Pharmacovigilance, QPPV

Zurab Koberidze has over 20 years of experience in clinical trials, health care management, monitoring, donor liaison and pharmacovigilance. Having gained his degrees from Tajik State Medical University and UC Berkeley and before joining FGK, Dr. Koberidze worked in clinical settings and later on for a charity, where he supervised advised humanitarian field projects in developing countries. His medical safety and pharmacovigilance expertise covers among others oncology, cardiology, dermatology and cardiovascular diseases. Dr. Koberidze is a highly experienced professional with a truly global perspective on medical practice.

Download CV (PDF: 107KB)

Oliver Wiedemann, M.D., Ph.D


Oliver Wiedemann is a medical doctor and has over 25 years of experience in pharmaceutical medicine, including work in pharmacovigilance, where he was/is also acting as QPPV. He hold various positions in large and small pharmaceutical companies, providing medical expertise for OTC, RX and Orphan Drug products in numerous indications. Dr. Wiedemann was responsible for the realisation of national and international phase II and III clinical studies as well as post marketing studies. Dr. Wiedemann gained his degrees from the Medical Faculty of the Ludwig-Maximilians-University in Munich.

Download CV (PDF: 103KB)